IDH1 and acute myeloid leukemia: Comutations in DNMT3A [18], TET2 [19, 20] or IDH1/2 [21, 22] have been shown to be adverse predictors, and NRAS [23], FLT3-TKD [24] or moCEBPA [25] have been shown to be favorable predictors of clinical outcome in NPM1mut/FLT3-ITD(−)/low AML.